Reid Hoffman is leaving Microsoft’s board to go ‘founder mode’ with startup Manus

Reid Hoffman is leaving Microsoft’s board to go founder mode with startup Manus, signaling a major shift in his professional trajectory and the broader landscape of AI and biotech. Hoffman, who joined Microsoft’s board following the $26.2 billion acquisition of LinkedIn in 2016, has played a pivotal role in guiding the tech giant’s strategic direction, particularly in the realm of artificial intelligence. Now, with his exit from the board, he is pivoting toward a more active role as the chairman and co-founder of Manus, an AI-driven drug discovery firm focused on combating cancer. This move underscores Hoffman’s belief in the potential of AI to revolutionize scientific innovation and his desire to be more directly involved in shaping that future.

A Strategic Exit from Corporate Governance

Hoffman’s tenure on Microsoft’s board was defined by high-stakes decisions that shaped the company’s long-term strategy. One of the most notable was Microsoft’s initial $1 billion investment in OpenAI in 2019, a move that positioned the tech giant as a major player in the AI space. As one of OpenAI’s earliest investors, Hoffman helped steer Microsoft’s AI ambitions, which have since grown into a multi-billion-dollar commitment. His departure from the board, while a personal career shift, also highlights the growing challenges of balancing corporate interests with individual ventures, especially in a field as fast-moving and competitive as AI.

Founding a New Frontier in AI-Driven Drug Discovery

Manus, the startup Hoffman is now fully committing to, represents a bold new frontier where artificial intelligence meets biotechnology. The company has already raised over $50 million in seed funding and is led by Dr. Siddhartha Mukherjee, a physician and Pulitzer Prize-winning author known for his groundbreaking work in cancer research. Hoffman’s role as chairman and co-founder reflects his confidence in Manus’s mission to develop Move 37, an AI system designed to outperform human creativity in chemical innovation. This system is expected to play a critical role in advancing cancer treatments and could redefine how drug discovery is approached in the future.

Manus is leveraging AI to accelerate drug discovery in several key ways:

• Using machine learning to predict molecular interactions and identify new drug candidates.
• Applying AI to analyze vast amounts of biological data more efficiently than traditional methods.
• Creating a platform that bridges the gap between computational models and real-world pharmaceutical research.

Hoffman’s vision for Move 37 is to revolutionize chemistry through machine learning, enabling the development of novel compounds that could be used in life-saving treatments. The startup’s leadership includes experts from both science and publishing, creating a unique blend of technical and narrative-driven insight that could drive its success.

While Hoffman is stepping down from Microsoft’s board, his influence on the company’s AI trajectory is unlikely to wane. Microsoft has continued to expand its AI initiatives, including its deepening partnership with OpenAI and its investments in generative AI tools. Hoffman’s move, however, highlights a broader trend: veteran tech leaders are increasingly choosing to return to the founder role, prioritizing hands-on innovation over corporate governance. This shift may reflect a growing desire among industry veterans to reclaim the entrepreneurial drive that initially brought them to prominence.

The decision also raises questions about the evolving dynamics between corporate boards and the founders they once counted on. As AI startups like Manus gain traction, the line between investor and operator becomes increasingly blurred. Hoffman’s transition from board member to active founder may signal a new era in which tech veterans seek to return to the core of innovation, much like they did in the early days of their careers.

Looking ahead, Manus’s progress will be a key indicator of whether Hoffman’s return to founder mode can deliver the same kind of transformative impact that LinkedIn did in its early years. If successful, the startup could redefine the role of AI in medicine — and perhaps even challenge the status quo of pharmaceutical innovation. For now, the departure of one of Microsoft’s most influential board members marks a clear turning point in both his career and the AI ecosystem he helped build.